Major anti-breast cancer drug off patent: Government in Parliament; room for cheaper generics : The Tribune India

Join Whatsapp Channel

Major anti-breast cancer drug off patent: Government in Parliament; room for cheaper generics

While the branded Palbociclib drug version cost over Rs 80,000 a month, the generic formulations now available have cut the drug cost by over 90 pc to around Rs 3800 a month

Major anti-breast cancer drug off patent: Government in Parliament; room for cheaper generics

Photo for representational purpose only. iStock



Tribune News Service

New Delhi, March 28

The government on Tuesday informed Parliament that a major anti-breast cancer drug, Palbociclib, had gone off patent, creating opportunities for production of generic versions.

While the branded Palbociclib drug version cost over Rs 80,000 a month, the generic formulations now available have cut the drug cost by over 90 pc to around Rs 3800 a month.

The generic versions are currently either being produced or are in the process of being manufactured by around 15 pharmaceutical companies in India, health ministry sources said.

This was made possible after Pfizer’s Indian patent on Palbociclib expired on January 10 this year.

The Minister of State for Health in her answer on breast cancer drug availability, informed the Rajya Sabha today that as per the ICMR-National Cancer Registry Programme data, the estimated number of incidenceof breast cancer in the country for the year 2022 is 216108.

“As per Central Drugs Standard Control Organisation (CDSCO, palbociclib has gone offpatent on January 10, 2023.As informed by Department of Pharmaceuticals, National Pharmaceutical Pricing Authority vide dated February 27, 2019, has put a cap on Trade Margin of 42 selected nonscheduled anti-cancer medicines on pilot basis under ‘Trade Margin Rationalization’ approach. Anti-breast cancer drug Ribociclib was also included in this,” Pawar said.

Importantly nearly half the breast cancer patients detected annually out of around 14 lakh overall cancer patients, half (nearly 1.2 lakh) require Palbociclib, which is prescribed in combination with hormonal treatments.

Palbociclib is normally prescribed for 18 months with the generic drug version costing around Rs 3800 a month instead of Rs 80,000 previously.

Sun Pharmaceuticals was the first to launch a generic version of Pfizer’s palbociclib in India on January 11.

About The Author

The Tribune News Service brings you the latest news, analysis and insights from the region, India and around the world. Follow the Tribune News Service for a wide-ranging coverage of events as they unfold, with perspective and clarity.

#cancer


Top News

‘Absolutely not, won't take those who left us’: Uddhav Thackeray shuts door for former party colleagues

No question of taking back rebels: Uddhav, Sharad Pawar after MVA's stellar LS performance

This statement by Thackeray came after Maha Vikas Aghadi (MV...

8 dead as tempo traveller with 17 people falls in Alaknanda river on Rishikesh-Badrinath highway

10 dead as tempo traveller with 26 people falls into Alaknanda river on Rishikesh-Badrinath highway

Police say the victims of the accident were tourists on the ...

2 Punjab's Nurmahal cousin sisters shot at by Nakodar boy in US, one succumbs to wounds

2 Punjab's Nurmahal cousin sisters shot at by Nakodar boy in US, one dies of wounds

Accused Gaurav and one of victims pursued IELTS together at ...

8 Naxalites, security personnel killed in encounter in Chhattisgarh’s Narayanpur

8 Naxalites, STF jawan killed in encounter in Chhattisgarh’s Narayanpur

The gunfight broke out in Abhujmad forest area of Narayanpur...


Cities

View All